These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16402668)

  • 1. HIV and increased risk of cardiovascular diseases.
    Das S
    Sex Health; 2005; 2(4):219-21. PubMed ID: 16402668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.
    Barbaro G
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):337-43. PubMed ID: 16101566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular risk factors associated with antiretroviral therapy].
    Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 7. ART regimes and fat: the healing hand wielding the sword.
    Domingo P; Espinet J; Vidal F
    Lancet HIV; 2017 Jan; 4(1):e2-e3. PubMed ID: 27815067
    [No Abstract]   [Full Text] [Related]  

  • 8. [HIV infection: emerging issues and new challenges].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic complications of HIV therapy in children.
    McComsey GA; Leonard E
    AIDS; 2004 Sep; 18(13):1753-68. PubMed ID: 15316336
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV infection, highly active antiretroviral therapy and the cardiovascular system.
    Barbaro G
    Cardiovasc Res; 2003 Oct; 60(1):87-95. PubMed ID: 14522410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
    Grinspoon SK
    Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients.
    Tomazic J; Silic A; Karner P; Vidmar L; Maticic M; Poljak M; Ihan A; Janez A
    Wien Klin Wochenschr; 2004 Nov; 116(21-22):755-9. PubMed ID: 15628647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy.
    Asensi V; Martín-Roces E; Carton JA; Collazos J; Maradona JA; Alonso A; Medina M; Aburto JM; Martínez E; Rojo C; Bustillo E; Fernández C; Arribas JM
    Clin Infect Dis; 2004 Jul; 39(2):240-7. PubMed ID: 15307034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
    Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.
    Sánchez Torres AM; Munoz Muniz R; Madero R; Borque C; García-Miguel MJ; De José Gómez MI
    Eur J Pediatr; 2005 May; 164(5):271-6. PubMed ID: 15650834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
    Grinspoon S; Carr A
    N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.